

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 May 2024 (02.05.2024)



(10) International Publication Number
WO 2024/092152 A1

- (51) **International Patent Classification:**
A61K 35/17 (2015.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/US2023/077950
- (22) **International Filing Date:**
26 October 2023 (26.10.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|-------------------------------|----|
| 63/381,525 | 28 October 2022 (28.10.2022) | US |
| 63/386,457 | 07 December 2022 (07.12.2022) | US |
| 63/479,877 | 13 January 2023 (13.01.2023) | US |
| 63/515,492 | 25 July 2023 (25.07.2023) | US |

(71) **Applicant:** KITE PHARMA, INC. [US/US]; 2400 Broadway, Santa Monica, California 90404 (US).

(72) **Inventors:** BUDKA, Justin A.; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). GARCIA, Rhine Shen; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). KANSKA, Justyna E.; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). KLOOS, Ioana Magdalena; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). NIKO-LAENKO, Liana; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). WOLTHERS, Benjamin Ole; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) **Agent:** SANNY, Tony et al.; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(54) **Title:** IMPROVING EFFICACY AND DURABLE RESPONSE OF IMMUNOTHERAPY

(57) **Abstract:** Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy. Further provided are methods for treatment of a cancer patient with such cells.

WO 2024/092152 A1